TrialAmerican journal of hematology2016

A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia.

Ian W Flinn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.